BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28853695)

  • 1. Paradoxical results obtained with Ki67-labeling and PHH3-mitosis index in glial tumors: a literature analysis.
    Elmaci İ; Altinoz MA; Bolukbasi FH; Yapicier O; Sav A
    Clin Neuropathol; 2017; 36(6):272-282. PubMed ID: 28853695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
    Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
    Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
    Tracht J; Zhang K; Peker D
    J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated Histone H3 (PHH3) as a Novel Cell Proliferation Marker and Prognosticator for Meningeal Tumors: A Short Review.
    Elmaci İ; Altinoz MA; Sari R; Bolukbasi FH
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):627-631. PubMed ID: 28777144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
    Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
    Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
    Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
    Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
    Medani H; Elshiekh M; Naresh KN
    J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
    Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
    Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
    van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
    Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.
    Uguen A; Conq G; Doucet L; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Virchows Arch; 2015 Jul; 467(1):47-54. PubMed ID: 25823616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
    Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
    Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
    Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPIGENETIC CHANGES - HISTONE 3 PHOSPHORYLATION - EPITHELIAL OVARIAN TUMORS.
    Munjishvili V; Barabadze E; Muzashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 Sep; (294):128-131. PubMed ID: 31687964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
    Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.
    Zhu P; Zhang CB; Yang P; Chen J; Liu YQ; Hu HM; Huang H; Bao ZS; Zhang W; Kong WJ; Jiang T
    Oncotarget; 2016 Jul; 7(29):45005-45014. PubMed ID: 27323851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count.
    Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM
    Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.